Christen A. Khella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christen A. Khella has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Michael L. Gatza
Rutgers Cancer Institute of New Jersey, New Brunswick, USA
45 shared publications - Karthikeyan Mythreye
University of Alabama at Birmingham 6 Department of Pathology and O'Neal Comprehensive Cancer Center, Heersink School of Medicine Birmingham, Alabama
40 shared publications - Lorna Rodriguez-Rodriguez
14Division of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Los Angeles, California
40 shared publications - Lucyann Franciosa
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
40 shared publications - Resha Rajkarnikar
Department of Pathology, University of Alabama at Birmingham, Birmingham, Heersink School of Medicine, Birmingham, Alabama, USA
40 shared publications Gaurav A. Mehta
Department of Radiation Oncology, Robert Wood Johnson Medical School, New Brunswick, USA
2 shared publications
Latest Publications
- Open Access
- 17 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Loss of ALK4 promotes cancer progression through regulating TGF-β receptor N-glycosylation
The transforming growth factor-β (TGF-β) pathway typically inhibits tumorigenesis but can promote metastasis during cancer progression. Activin receptor-like kinase 4 (ALK4), a type I TGF-β family receptor, is frequently downregulated or mutated in cancers, and reduced ALK4 expression correlates with poorer outcomes. However, its role and mechanism of action in cancer progression remains unclear. We demonstrate that ALK4 loss enhances anchorage-independent growth, migration, invasion, and epithelial-mesenchymal transition in vitro, as well as cancer progression in breast and pancreatic cancer models in vivo. Importantly, ALK4 loss promotes canonical TGF-β signaling by increasing TGF-β receptor N-linked glycosylation and stabilizing these receptors at the cell surface. Mechanistically, ALK4 loss upregulates β1,6 N-acetylglucosaminyltransferase V (MGAT5) and galectin-3, which binds MGAT5-modified glycoproteins to stabilize surface receptors. Consistent with prior observations that galectin-3 preferentially binds to MGAT5-modified glycoproteins to stabilize cell surface receptors like TGF-β receptors, we demonstrate that ALK4 loss enhances MGAT5-mediated glycosylation of TGF-β receptors, promoting their stabilization and signal transduction. Depleting MGAT5 or inhibiting N-glycosylation effectively suppresses ALK4-loss-induced TGF-β signaling and cancer progression.
- 17 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessLoss of ALK4 promotes cancer progression through regulating TGF-β receptor N-glycosylation
The transforming growth factor-β (TGF-β) pathway typically inhibits tumorigenesis but can promote metastasis during cancer progression. Activin receptor-like kinase 4 (ALK4), a type I TGF-β family receptor, is frequently downregulated or mutated in cancers, and reduced ALK4 expression correlates with poorer outcomes. However, its role and mechanism of action in cancer progression remains unclear. We demonstrate that ALK4 loss enhances anchorage-independent growth, migration, invasion, and epithelial-mesenchymal transition in vitro, as well as cancer progression in breast and pancreatic cancer models in vivo. Importantly, ALK4 loss promotes canonical TGF-β signaling by increasing TGF-β receptor N-linked glycosylation and stabilizing these receptors at the cell surface. Mechanistically, ALK4 loss upregulates β1,6 N-acetylglucosaminyltransferase V (MGAT5) and galectin-3, which binds MGAT5-modified glycoproteins to stabilize surface receptors. Consistent with prior observations that galectin-3 preferentially binds to MGAT5-modified glycoproteins to stabilize cell surface receptors like TGF-β receptors, we demonstrate that ALK4 loss enhances MGAT5-mediated glycosylation of TGF-β receptors, promoting their stabilization and signal transduction. Depleting MGAT5 or inhibiting N-glycosylation effectively suppresses ALK4-loss-induced TGF-β signaling and cancer progression.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Fig S2 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
The source of elevated HCK signature is not due to a bias in tumor purity or immune infiltration.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig S2 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
The source of elevated HCK signature is not due to a bias in tumor purity or immune infiltration.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Summary of the IHC staining of HCK in ovarian cancer tissue microarrays.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Summary of the IHC staining of HCK in ovarian cancer tissue microarrays.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Summary of differentially expressed proteins (RPPA analysis) following HCK silencing in CAOV3 cells
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Summary of differentially expressed proteins (RPPA analysis) following HCK silencing in CAOV3 cells
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Table S2 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Table S2 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Fig S4 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
The effect of GSIs on NOTCH3 ICD expression in HGSOC cells following HCK overexpression.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig S4 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
The effect of GSIs on NOTCH3 ICD expression in HGSOC cells following HCK overexpression.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Fig S1 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Distribution of clinical features associated with poor and good prognostic HGSOC patient samples in the TCGA U133A dataset.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig S1 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Distribution of clinical features associated with poor and good prognostic HGSOC patient samples in the TCGA U133A dataset.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Fig S3 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Cell line selection and engineering
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFig S3 from HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling
Cell line selection and engineering
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from HCK promotes high-grade serous ovarian cancer tumorigenesis through CD44 and NOTCH3 signaling
Summary of differentially expressed proteins (RPPA analysis) following HCK silencing in CAOV3 cells
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from HCK promotes high-grade serous ovarian cancer tumorigenesis through CD44 and NOTCH3 signaling
Summary of differentially expressed proteins (RPPA analysis) following HCK silencing in CAOV3 cells
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Fig S2 from HCK promotes high-grade serous ovarian cancer tumorigenesis through CD44 and NOTCH3 signaling
The source of elevated HCK signature is not due to a bias in tumor purity or immune infiltration.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFig S2 from HCK promotes high-grade serous ovarian cancer tumorigenesis through CD44 and NOTCH3 signaling
The source of elevated HCK signature is not due to a bias in tumor purity or immune infiltration.